

Pembrolizumab: The New Standard of Care in Advanced Lung Cancer

Thursday, 12 April 2018
18:40 – 19:40

Scientific Symposium
Sponsored by MSD

Palexpo
Room A
Geneva, Switzerland

Chair: Martin Reck (Germany)

CHAIR

Martin Reck

Head of the Department of Thoracic
Oncology
Lung Clinic Grosshansdorf
Grosshansdorf, Germany

FACULTY

Natasha Leighl

Professor
Princess Margaret Cancer Centre
University of Toronto
Toronto, Canada

Rolf Stahel

Professor, Chair
Comprehensive Cancer Center Zurich
University Hospital Zurich
Zurich, Switzerland

Educational Objectives

- Present a critical review of the current immune checkpoint inhibitor landscape for patients with lung cancer, with emphasis on appropriate patient selection based on latest biomarker data
- Educate on current thinking regarding sequencing, rechallenge, and quality-of-life data associated with treatment of immunotherapies in patients with lung cancer

AGENDA

| | | |
|---------------|--|----------------|
| 18:40 | Welcome | Martin Reck |
| 18:40 – 18:55 | Anti-PD-1 Monotherapy in Metastatic NSCLC | Martin Reck |
| 18:55 – 19:10 | Practical Application of Anti-PD-1 Therapy | Natasha Leighl |
| 19:10 – 19:25 | What's Next for Anti-PD-1 Therapy in NSCLC | Rolf Stahel |
| 19:25 – 19:40 | Panel Discussion | Faculty |
| 19:40 | Closing Remarks | Martin Reck |